Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer

被引：10
|
作者：
Liu, Yi-Fu [1 ]
Fu, Sheng-Qiang [1 ]
Yan, Yu-Chang [1 ]
Gong, Bin-Bin [1 ]
Xie, Wen-Jie [1 ]
Yang, Xiao-Rong [1 ]
Sun, Ting [1 ]
Ma, Ming [1 ]
机构：
[1] Nanchang Univ, Affiliated Hosp 1, Dept Urol, Nanchang 330000, Jiangxi, Peoples R China
来源：
DRUG DESIGN DEVELOPMENT AND THERAPY | 2021年 / 15卷
关键词：
gonadotropin-releasing hormone; prostate cancer; degarelix; relugolix; ANDROGEN-DEPRIVATION THERAPY; ANTIANDROGEN FLARE PROTECTION; URINARY-TRACT SYMPTOMS; III EXTENSION TRIAL; OF-LIFE IMPROVEMENT; OPEN-LABEL; GNRH ANTAGONIST; PHASE-II; JAPANESE PATIENTS; 1-ARM CROSSOVER;
D O I：
10.2147/DDDT.S291369
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Gonadotropin-releasing hormone (GnRH) receptor agonists are still the most commonly used androgen deprivation treatment (ADT) drugs for prostate cancer in clinical practice. Currently, the GnRH receptor antagonists used for endocrine therapy for prostate cancer primarily include degarelix and relugolix (TAK-385). The former is administered by subcutaneous injection, while the latter is an oral drug. Compared to GnRH agonists, GnRH antagonists reduce serum testosterone levels more rapidly without an initial testosterone surge or subsequent microsurges. This review focuses on the mechanism of action of GnRH antagonists and agonists, the developmental history of GnRH antagonists, and emerging data from clinical studies of the two antagonists used as endocrine therapy for prostate cancer.
引用
收藏
页码：639 / 649
页数：11
相关论文
共 50 条
  • [31] Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer
    Smith, MR
    Boyce, SP
    Moyneur, E
    Duh, MS
    Raut, MK
    Brandman, J
    JOURNAL OF UROLOGY, 2006, 175 (01): : 136 - 139
  • [32] Model of gonadotropin-releasing hormone and gonadotropin-releasing hormone complex
    Wiwanitkit, Viroj
    SEXUALITY AND DISABILITY, 2006, 24 (03) : 175 - 178
  • [33] Model of gonadotropin-releasing hormone and gonadotropin-releasing hormone complex
    Viroj Wiwanitkit
    Sexuality and Disability, 2006, 24 : 175 - 178
  • [34] CLINICAL APPLICATIONS OF GONADOTROPIN-RELEASING HORMONE
    MORTIMER, CH
    CLINICS IN ENDOCRINOLOGY AND METABOLISM, 1977, 6 (01): : 167 - 179
  • [35] Uracils as potent antagonists of the human gonadotropin-releasing hormone receptor without atropisomers
    Guo, ZQ
    Chen, YS
    Huang, CQ
    Gross, TD
    Pontillo, J
    Rowbottom, MW
    Saunders, J
    Struthers, S
    Tucci, FC
    Xie, Q
    Wade, W
    Zhu, YF
    Wu, DP
    Chen, C
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (10) : 2519 - 2522
  • [36] CLINICAL STUDIES WITH GONADOTROPIN-RELEASING HORMONE
    JEWELEWICZ, R
    DYRENFURTH, I
    WARREN, M
    VANDEWIE.RL
    BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 1974, 50 (10) : 1097 - 1119
  • [37] Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer
    Smith, Matthew R.
    CLINICAL CANCER RESEARCH, 2007, 13 (01) : 241 - 245
  • [38] Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor-positive human cancer cell lines
    Palyi, I
    Vincze, B
    Kalnay, A
    Turi, G
    Mezo, I
    Teplan, I
    Seprodi, J
    Pato, J
    Mora, M
    CANCER DETECTION AND PREVENTION, 1996, 20 (02): : 146 - 152
  • [39] Gonadotropin-releasing hormone receptors in prostate tissue
    Bono, AV
    Salvadore, M
    Celato, N
    ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY, 2002, 24 (04): : 221 - 227
  • [40] The role of gonadotropin-releasing hormone antagonists in in vitro fertilization
    Diedrich, K
    Ludwig, M
    Felberbaum, RE
    SEMINARS IN REPRODUCTIVE MEDICINE, 2001, 19 (03) : 213 - 220
12345